Showing Results for: “diabetes exercise”

“This is an historic moment for all people affected by type 1 diabetes (T1D). The approval of Teplizumab, the first-ever treatment approved for the delay of T1D, is a significant step forward for everyone impacted by this chronic disease. People with T1D require life-long insulin replacement therapy, so to be able to provide an individual with a 2-year delay from the symptoms and burden of T1D is a tremendous accomplishment as we look towards finding a cure. There will likely be long-term benefits for blood glucose management and the reduction or delay of acute and long-term complications. The

Participating, approved products will display the mark on select products to inform consumers The American Diabetes Association (ADA) is pleased to announce the launch of the Better Choices for Life program. The program is designed to aid shoppers in making better choices while shopping and is currently in its pilot stage. Products are selected through a science and evidence-based approach. At this time, prescription drugs are not evaluated or considered for the program. Following an extensive evaluation process, companies applying for participation and passing the evaluation may place the

The Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) trial has found dulaglutide, an injectable, glucagon-like peptide-1 (GLP-1) receptor agonist, demonstrates superiority in the reduction of cardiovascular events for a broad range of people living with type 2 diabetes (T2D), according to research presented today at a symposium at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions®. The REWIND trial is the first study to include a majority of participants (69%) with no history of cardiovascular disease (CVD) at enrollment. Additionally, the

On October 5, 2021, Medtronic announced the expansion of two recalls on MiniMed 600 series insulin pumps for incorrect insulin dosing and remote controllers used with Paradigm and 508 MiniMed insulin pumps for potential cybersecurity risks. The U.S. Food and Drug Administration (FDA) has identified both of these as Class I recalls, the most serious type of recall. People with diabetes who are currently using a MiniMed 600 series insulin pump and are unsure if their device is affected, should refer to the Medical Device Recalls database or use the Medtronic Pump Serial Number Look-up Tool . If

People with type 2 diabetes should be considered in remission after sustaining normal blood glucose (sugar) levels for three months or more, according to a new consensus statement from the American Diabetes Association ® (ADA), the Endocrine Society, the European Association for the Study of Diabetes and Diabetes UK jointly published in Diabetes Care , the J ournal of Clinical Endocrinology & Metabolism , Diabetologia , and Diabetic Medicine , respectively. About 10% of the U.S. population has diabetes , and these numbers continue to rise. People with type 2 diabetes can achieve “remission” by

Study shows diabetes patients not taking medication experienced longer hospitalization and recovery with greatest toll among Latinx populations A new study reveals unmanaged diabetes is a key factor in COVID-19 severity and complications, particularly among Hispanic and Latinx populations. Findings of the retrospective study were presented at the virtual 81st Scientific Sessions of the American Diabetes Association ® (ADA). Forty percent of Americans who have died of COVID-19 have had diabetes, and 1 in 10 people with diabetes hospitalized for COVID-19 die within one week – making diabetes a

Analysis of large international DAPA-HF trial participants notes diabetes prevention benefit in patients with heart failure who took 10 mg of medication The SGLT2 inhibitor dapagliflozin, when used in patients with heart failure, provided a benefit in preventing type 2 diabetes (T2D), according to the study, “Effect of Dapagliflozin on the Incidence of Diabetes: A Prespecified Exploratory Analysis from DAPA-HF,” presented today at the American Diabetes Association’s® (ADA’s) 80th Virtual Scientific Sessions. The original DAPA-HF trial was a phase 3 placebo-controlled international study of

Browse list of diabetes-related terms and their definitions- Adapted from NIDDK.

First-of-its-Kind Program Addresses Growing Need for Improved Diabetes Care Today, the American Diabetes Association® (ADA) announced a new partnership with The Leapfrog Group, an independent national watchdog focused on health care safety, to launch the first-ever national designation program that will recognize hospitals demonstrating a strong commitment to the safety and well-being of inpatients who are living with diabetes. “Studies show that patients with diabetes often face heightened risks of serious health complications when visiting hospitals. That is especially true for patients of

The American Diabetes Association announces a new partnership to advance consumer resources for successful foot care The American Diabetes Association ® (ADA), the nation’s leading volunteer health organization, announced a new partnership with Dr. Comfort, to provide foot care resources on an ADA platform in a journey-driven experience for those living with diabetes and their caregivers. Dr. Comfort is a national sponsor of Living with Diabetes: Foot Care & Amputation . The Foot Care & Amputation section of the platform leads each user to learn to care for their feet, understand foot